Of note, data from this study indicated that activation of Hh signaling in chondrosarcoma cancer cells is type I noncanonical Hh signaling (GLI1-dependent and SMO-independent) since the Hh pathway activity can be diminished by GLI1 knockdown, but not by cyclopamine treatment. The gene discussed is SMO; the disease is chondrosarcoma.